Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Event context and recent share performance
Novo Nordisk (NYSE:NVO) has come back into focus for investors after a period of weaker share performance, with the stock showing negative returns over the past month, past 3 months, and year to date.
At a share price of US$36.04, Novo Nordisk’s recent 30 day share price return of a 3.77% decline and 1 year total shareholder return of a 47.69% decline suggest momentum has been fading rather than building.
If you are weighing Novo Nordisk against other healthcare names, it can be useful to see what else is moving in the sector and compare with 33 healthcare AI stocks
With a share price of US$36.04, single digit revenue and net income growth, and indications of a large intrinsic discount, is Novo Nordisk now trading below its underlying worth, or is the market already pricing in future growth?
Most Popular Narrative: 62.1% Undervalued
According to the most followed narrative on Novo Nordisk, the current share price of $36.04 sits well below an assessed fair value of $95, which frames the recent weakness as a valuation reset rather than a broken business.
We estimate fair value at ~$95 per ADR (base-case range $90–$100), reflecting a more competitive, more price-sensitive regime than the peak GLP-1 narrative, but also acknowledging the durability of the franchise and the expanding product/indication set.
Curious what has to happen for that gap to close? This narrative leans on specific assumptions for revenue growth, profit margins, and future earnings multiples that materially shape the $95 figure.
Result: Fair Value of $95 (UNDERVALUED)
However, this hinges on key swing factors, including how far US pricing pressure goes on GLP 1 drugs and whether competitors erode Novo Nordisk’s obesity and diabetes share faster than expected.